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Introduction
The use of vitamin D in the prevention and treatment of cancer began when 1,25(OH)2D3
showed antiproliferative activity against cancer cells and decreased levels of 25- hydroxyvitamin D3 (25(OH)D3) in serum were detected in cancer patients [1] . Many in vitro
and in vivo studies have demonstrated that 1,25(OH)2D3 expresses antitumor activity by regulating processes such as proliferation, differentiation, apoptosis, and angiogenesis [2] .
1,25(OH)2D3, via the vitamin D receptor (VDR) receptor, associates with the vitamin D
response element present in the promoter region of many genes in the cell, for example, those responsible for the above processes, that is for activating or inhibiting the transcription of genes, thus regulating their expression [3, 4] . Apart from VDR, there are also other nuclear receptors that are targets for vitamin D hydroxyderivatives including retinoic acid-related orphan receptors α-γ (RORα and RORγ) that play a role in embryonic development, differentiation, several immune pathways, metabolism [5, 6] and aryl hydrocarbon receptor (AhR) of toxicity-related pathway that control cell response to toxic and carcinogenic compounds [7] . Moreover, vitamin D was also shown to enhance the anticancer effect of many different small molecules [8] [9] [10] [11] [12] . The use of 1,25(OH)2D3 and vitamin D derivatives (VDDs) was reported [13] [14] [15] in the therapy of various types of cancer, including breast, prostate, large intestine, leukemia, and lung cancer. VDDs are already used in clinics to treat hyperproliferative skin disorders like psoriasis or in osteoporosis, and secondary hyperparathyroidism [14] . For example, calcipotriol revealed efficacy and safety in the topical A C C E P T E D M A N U S C R I P T treatment of psoriasis. There are studies aimed at obtaining new VDDs that can be metabolically activated in the skin to exert their effect locally with limited systemic side effects [16, 17] . There are also studies showing that there are novel hydroxy-derivatives of D3 different from 25(OH)D3 and 1,25(OH)2D3 and that are produced by CYP11A1-initiated secosteroidal pathways, which show antiproliferative, prodifferentiation and antiinflammatory activity, comparable to or even better than those of 1,25(OH)2D3 [18, 19] .
CYP11A1 also converts synthetic prohormone 1-hydroxyvitamin D3 (1(OH)D3), used in the treatment of osteoporosis, rickets and hypocalcemia, to the biologically active 1,20(OH)2D3 as an alternative pathway to the production of 1,25(OH)2D3 from that prodrug 1(OH)D3 [20] .
1,25(OH)2D3 and many VDDs showed antiproliferative effects on many types of VDRexpressing cancer cells, including lung cancer cells [1, 21, 22] . In lung cancer animal models, 1,25(OH)2D3 inhibited tumor growth and demonstrated lower tumor cell metastasis in the Lewis lung cancer model. 1,25(OH)2D3 also increased immune response against cancer [23, 24] and inhibited B16 melanoma lung metastasis [25] . Vitamin D supplementation also reduced the incidence of cancer in mice with lung cancer induced with different carcinogens [1, 26] . Moreover, significant association was found between nuclear VDR expression and overall survival in lung cancer patients [27] . Additionally, mRNA expression of CYP24A1 was elevated in lung adenocarcinoma and highly expressed CYP24A1 was correlated with poorer 5-year survival [28] . Therefore, there is still a great potential for VDDs in lung cancer treatment.
Several polymorphisms have been identified in the coding sequence of the VDR gene. One of them is the rs2228570 (FokI) polymorphism located in the fourth exon of the VDR gene, which refers to the translation initiation site. The change of the T (ATG, Met) residue into C (ACG, Thr), G (AGG, Arg), or A (AAG, Lys) residues causes variation in the nucleotide A C C E P T E D M A N U S C R I P T sequence. As a result, two variants of the VDR protein may be formed in the translation process: a longer form and a shorter form of VDR protein. The longer form, containing 427 amino acids, is biologically two times less active than the shorter one which is built up of 424 amino acids [29] . Two single nucleotide polymorphisms (SNPs) in the VDR gene introns (rs1544410, BsmI and rs7975232, ApaI), as well as a synonymic polymorphic variant in the 11th exon (rs731236, TaqI; Ile > Ile) were also frequently investigated and identified as having the greatest impact on VDR function. The 3′ untranslated region (3′UTR) is responsible for the regulation of gene expression, in particular for the stability of mRNA. Two major variants of the VDR 3'UTR region have been identified: "baT" and "BAt." It appears that the incidence of "BAt" haplotype expression on mRNA level is higher in comparison to that of the "baT" haplotype. Also, the "BAt" protein seems to show better responses to vitamin D than the "baT" receptor, probably due to a slightly better mRNA stability and its half-life [29] . Occurrence of some alleles correlates with a greater response to 1,25(OH)2D3.
Colin et al. observed differences between rs2228570 genotypes of peripheral blood mononuclear cells and the ED50 of 1,25(OH)2D3. They observed the lowest ED50 value for the FF-genotype, intermediate ED50 for Ff-heterozygotes, and the highest ED50 value for the ffgenotype. No differences in ED50 or maximal proliferation inhibition were observed for the rs1544410, rs7975232, and rs731236 variants [30] .
Several genetic mutations responsible for the emergence and development of non-small cell lung cancer are known. Among them, the most frequent are mutations in the epithelial growth factor receptor (EGFR) gene, KRAS (Kirsten rat sarcoma viral oncogene homologue), p53 proteins and rearrangement of the ALK (anaplastic lymphoma kinase) and EML4. EGFR and KRAS mutations occur independently in lung cancer [31, 32] . EGFR and KRAS induces many signaling pathway, like Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR that regulate cell proliferation, differentiation and apoptosis [33] . p53, known as guardian of the genome is A C C E P T E D M A N U S C R I P T a multifunctional transcription factor that controls many cellular processes like cell cycle progression, cell death, the maintenance of genomic stability, senescence and many others [34] .
In the present study we investigated the correlation between the diverse structure of a panel of VDDs and their antiproliferative activity against a number of selected human lung cancer cell lines (Table 1) . With the aim of developing a lead VDD for structure optimization in lung cancer, in this study we used analogs that had previously shown some potential with other cancer cell line models [35] : 25-hydroxylated and 25-nonhydroxylated analogs, side-chain homologated and/or unsaturated analogs, side-chain hydroxylated analogs, 5,6-trans, and 19-nor analogs of 1-hydroxylated vitamin D2 and D3. Moreover, we investigated the influence of VDR and CYP24A1 expression levels, and also VDR polymorphisms, in these cells on the activity profile of our selected VDDs. [36] A549 AD mut wt* wt [36] [37] [38] NCI-H358 BAC mut null* wt [36, 38, 39] Calu-3 AD wt mut* wt [38] NCI-H1703 SCC wt mut wt [38] NCI-H1299 AD wt # null* wt [37, 40] HCC827 AD wt wt mut [37, 39] *According to "The TP53 web site" http://p53.free.fr/Database/Cancer_cell_lines/NSCLC.html.
NSCLC-non small cell lung cancer, AD-adenocarcinoma, BAC-bronchioalveolar carcinoma, SCC-squamous cell carcinoma, wt-wild type, mut -mutant, #-NCI-H1299 is NRAS mutant. Limited, Paisley, UK) with the addition of 10% FBS (GE Healthcare, Logan UT, USA). All culture media were supplemented with antibiotics: 0.1 mg/mL streptomycin and 100 U/mL penicillin (Sigma-Aldrich, Steinheim, Germany and Polfa Tarchomin, Warsaw, Poland respectively). Cells were cultured in an auto flow water jacket CO2 incubator NU-5510 E (NuAire, Plymouth MN, USA) at 37ºC, in humidified atmosphere saturated with 5% CO2.
Materials and methods

Cell lines
Compounds
VDDs ( Figure 1 IC50 value (concentration of the tested compound that inhibits cell proliferation by 50%) for cisplatin was calculated using Cheburator 0.4, Dmitry Nevozhay software for each experiment [41] . 
Western blot analysis
VDR polymorphism
DNA was isolated from cell cultures of human lung cancer using NucleoSpin (MachereyNagel INC, Bethlehem, PA, USA) in accordance with the manufacturer's protocol.
Genotyping was performed by polymerase chain reaction (PCR), followed by restriction fragment length polymorphism (RFLP) analysis ( Table 2 ). The rs2228570, rs1544410, rs7975232, and rs731236 VDR polymorphic variants were selected for the analysis. Primers 
Statistical evaluation
Statistical analysis was performed and graphs were prepared using GraphPad Prism 7
(GraphPad Software, Inc., San Diego, CA, USA). Four VDDs that exerted the highest mean proliferation inhibition on HCC827 cells at a concentration of 100 nM, PRI-1890, PRI-2171, PRI-2191, and PRI-5106, were tested in combination with cisplatin for their antiproliferative activity. As shown in Table 4 , the addition of VDDs at a concentration of 100 nM did not influence the cytotoxic activity of cisplatin in most of the tested cell lines. An exception to this rule was the HCC827 cell line in which stronger antiproliferative activity was observed (IC50 for the combination of cisplatin and VDDs was lower than for cisplatin alone), and the NCI-H358 cell line where a weaker activity of cisplatin after addition of VDDs was observed (higher value of IC50 reported for the combination of cisplatin and VDDs as compared to cisplatin alone). 
Results
Antiproliferative activity of VDDs
A C C E P T E D M A N U S C R I P TA C C E P T E D M A N U S C R I P T
A C C E P T E D
M A N U S C R I P
CYP24A1 and VDR expression in human lung cancer cell lines
In order to check whether the activity of VDDs on tested cell lines is dependent on the process of its metabolic inactivation, the expression of 24-hydroxylase CYP24A1 was analyzed in Densitometric analysis was performed using ImageJ 1.46v software. The results were normalized to actin. Representative blots are presented.
A C C E P T E D M
A N U S C R I P T
VDR polymorphism
We investigated the presence of the polymorphic variant responsible for the formation of a
shorter form of VDR in tested human lung cancer cells. In five (A549, Calu-3, HCC827, NCI-H1703, and NCI-H1299) of the seven examined cell lines, no variation was observed in the case of rs2228570 polymorphism-these cell lines are FF homozygotes, meaning that the longer and less transcriptionally active form of VDR protein, 427 amino acid is formed (Figure 3) . Furthermore, analysis of the presence of rs1544410, rs7975232, and rs731236 polymorphisms forming the "BAT" haplotype (responsible for intracellular mRNA stability of VDR) showed that in A549 and Calu-3 cells, the "baT" haplotype (leading to lower stability) is present. NCI-H1703 and NCI-H1299 cell lines were characterized by the "bAT"
and "BAT" haplotypes respectively (Figures 4-6 , Table 5 
Discussion
In this study we tested antiproliferative activity of 1,25(OH)2D3 and a number of structurally different VDDs on human lung cancer cell lines, differing in EGFR, KRAS, and p53 mutation status. Our research aimed at checking if cells with different genetic backgrounds of these three proteins were sensitive or resistant to the antiproliferative activity of VDDs. Our VDDs exhibited the highest proliferation inhibition on the HCC827 cell line (EGFR mutant). Lower activity was observed in A549 (KRAS mutant), NCI-H1299 (p53 null), and NCI-H1703 (p53 mutant) cells, while A-427 (KRAS mutant), Calu-3 (p53 mutant), NCI-H358 (KRAS mutant, p53 null) were mostly resistant. However, proliferation inhibition observed for four cell lines that responded to VDDs did not exceed 50% in our experimental conditions. Güzey et al. study, cells were exposed to tested compounds for as long as 10-14 days [42] . Some of VDDs used in this study on lung cancer cells had also been tested previously by our group in leukemia, lymphoma as well as one colon cancer and two breast cancer cell lines [43, 44] . It was shown that leukemia cells were the most sensitive to tested VDDs and the IC50 value (inhibitory concentration 50 -the dose of the tested compounds which inhibits proliferation of 50% of the cells) could be obtained for leukemia cells, while cancer cells of lymphoma and solid tumors like MCF-7, T47D, and HT-29 showed moderate proliferation inhibition even at a concentration of 1000 nM (13% to 50% proliferation inhibition depending on VDDs tested).
Moreover, it was shown that using VDDs on leukemia cells resulted in about 10-100 times higher activity than that of 1,25(OH)2D3 [43] . In our study on tested human lung cancer cells, VDDs revealed antiproliferative activity comparable to that of 1,25(OH)2D3 while having much lower calcemic side effects.
As it was anticipated, in tested human lung cancer cells, at the lower concentration of 100 nM, and PRI-2209, 5,6-trans-tacalcitol), highly active on other cancer cell lines [45] , were not very active on lung cancer cell lines A549, A-427, and NCI-H1703 and only moderately active on HCC827.
Of all the VDDs tested in this study, PRI-1890 [46] consistently showed the highest activity on the sensitive cell lines. However, contrary to our previous findings, the introduction of a very minor modification in the structure of PRI-1890 (one additional double bond at C-24a in the side-chain) resulted in an almost complete loss of activity of the resulting PRI-1901 [47] .
Several structure-activity correlations occurring at the higher concentration of 1000 nM have been retained at the lower concentration of 100 nM; however some other results are somewhat misleading. This is best represented by the relatively very high activity of 1-OH-D2 and 1-OH-D3 on a number of cell lines as compared to 1,25(OH)2D3 which is against the common knowledge in the field. Similarly, at the higher concentration, all VDDs studied showed activity comparable to that of 1,25(OH)2D3 on the most sensitive cell line, HCC827.
Very surprisingly, our 19-nor analogs [48] , except for the C-24 diastereomer of paricalcitol (PRI-5101) [43] , also showed low activity as compared Moreover, in tested lung cancer cells, there was no dependence on the mutation status (EGFR, KRAS, p53) or the ability to induce CYP24A1 expression.
Next, we analyzed the presence of VDR polymorphism in lung cancer cell lines to check whether it affects the response of tested cells to antiproliferative activity of VDDs. In studies focusing on VDR gene polymorphism, it was found that the occurrence of some alleles correlates with greater response to 1,25(OH)2D3. For example, 1,25(OH)2D3 was found to stimulate osteoblasts to secrete various amounts of osteocalcin, depending on the VDR allele present in these cells [55] . In psoriatic skin, it could be observed that clinical improvement was correlated with an increase in VDR mRNA when the skin was treated with 1,25(OH)2D3.
However, it was also noticed that not all patients suffering from psoriasis responded to treatment with VDDs. Some studies reported a correlation between VDR expression or VDR genotypes and psoriatic skin rash, as well as with responsiveness to treatment with VDDs.
Significant differences in VDR genotypes, rs7975232 (ApaI) and rs2228570 (FokI), between controls and patients suffering from psoriasis, but no difference in rs1544410 (BsmI) polymorphism were also noticed [16] . A number of studies were conducted to assess if there was a correlation between the risk of developing lung cancer and polymorphism of the VDR gene. Literature data are divergent in this respect: for example the rs731236 (TaqI) variant was shown to be a risk factor for developing lung cancer, but in another study it was suggested that this allele may, in turn, be a protective factor [56, 57] . Wu et al. reported a statistically significant correlation between VDR polymorphism and the reduction of nonsmall-cell lung carcinoma (NSCLC) risk. In this experiment, the rs1544410 (BsmI) and
rs731236 (TaqI) VDR polymorphisms were studied in 426 NSCLC patients and 445 controls from China [58] . The contradictory data may result from the different sizes of the study groups, the criteria used in the analysis, different genetic backgrounds etc. [56, 57] . Many studies have shown that VDD can augment the activity of chemotherapy even if VDDs themselves did not reveal any significant activity, and synergism with chemotherapeutic agents has been detected (reviewed in [59] ). In our study, we tested the influence of VDDs on the cytotoxic activity of cisplatin. Only in case of HCC827, among the tested cell lines, it could be observed that VDDs significantly augmented the cytotoxic activity of cisplatin. can modulate the transcriptional program guided by VDR, augmenting the expression of survival genes and reducing the expression of proapoptotic genes [61] . According to IARC TP53 Database (http://p53.iarc.fr/CellLines.aspx) and Takahashi et al. [62] , the NCI-H358 cell line has homozygous deletion of p53 and, therefore, the pro-survival effect of VDDs in these cells cannot be connected with mutant p53. We also checked the expression of p53 in this cell line by western blot and did not observe any band corresponding to p53 (data not shown). Therefore, the mechanism responsible for decreasing cytotoxic activity of cisplatin by VDDs requires further research.
Conclusions
Our extensive screening of structurally diverse classes of VDDs against a series of human lung cancer cell lines, differing in the genetic background of the three target proteins (EGFR, KRAS, and p53) as well as in VDR and CYP24A1 expression and VDR polymorphism, resulted in a differential response expressed as the inhibition of cell proliferation. Quite From this study we also concluded that lack of KRAS and p53 mutations in HCC827 cells may be responsible for the higher response of these cells to VDDs. On the other hand, the presence of mutations of KRAS and/or p53 in other cells block the antiproliferative activity of VDDs even though they are transcriptionally active in these cells, as assessed by increased CYP24A1 expression (e.g., NCI-H358). Other factors may also influence the sensitivity of these cells to VDDs. Very surprisingly, among two cell lines with null p53, NCI-H1299 and NCI-H358, a decreased cytotoxic activity of cisplatin upon VDD treatment was observed only in the latter. The mechanism causing this difference needs to be analyzed further.
Additionally, the polymorphic variants of the gene encoding the VDR present in human lung cancer cell lines tested are not directly responsible for the sensitivity of these cells to VDDs.
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